Public address

Kelly, Patrick
May 2004
Medical Marketing & Media;May2004, Vol. 39 Issue 5, p12
Trade Publication
Reports that Pfizer president Patrick Kelly responded when "The Wall Street Journal" accused pharmaceutical companies of price increases that would wipe out gains in pharmaceutical benefits for low-income seniors covered by Medicare. Kelly's contention that the article gave a distorted view of pricing practices, access programs, and complex factors behind increased costs for prescription drugs.


Related Articles

  • Pfizer takes leading role in drug-price debate. Arnold, Matthew // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p32 

    Reports on the launch of Helpful Answer, the brand for beefed-up roster of patient assistance programs by Pfizer Inc. in the U.S. Effort of the pharmaceutical industry to alleviate the high cost of drugs to uninsured Americas; Leadership role of Pfizer Inc. in drug-price debate; Expansion of the...

  • Policymakers eye increased prescription drug spending, PBM promotional activities. Wechsler, Jill // Formulary;Nov98, Vol. 33 Issue 11, p1147 

    Reports that United States policy makers are eyeing increased prescription drug spending and pharmacy benefit management promotional activities in light of the rising health care spending. Prediction for a major surge in health care spending; Congress' concern that developments are affecting...

  • What is the cost of administration really worth? Eder, Rob // Drug Store News;10/6/2003, Vol. 25 Issue 13, p14 

    Comments on the administrative costs of health care in the United States. Ways in which the rebate situation has made it impossible for a doctor to tell what drug is cheapest; Argument that the secretive rebate system of pharmacy benefits managers (PBM) moves more expensive drugs to the top of...

  • Prescription drug expenditures rising -- too fast?  // CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1261 

    Comments on the rising cost of prescription drugs in Canada. Rank of Canada among developed countries with the highest annual rate of prescription drug cost; Total cost of prescription drug cost in Canada in 2004; Discussion on the reasons for the rising cost of prescription drug in the country.

  • REQUIRED READING. Wechsler, Jill // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p26 

    Focuses on the report published in the journal "Health Affairs" about the rising national healthcare spending in the U.S. Clarification on the debate over whether high prices for new drugs are excessive or reasonable in relation to high research and development costs; Investment of...

  • Saving Money On Prescription Drugs. Meadows, Michelle // FDA Consumer;Sep/Oct2005, Vol. 39 Issue 5, p18 

    Provides information on the cost of drugs in the U.S. and how citizens can save money on medications. Risk involved in buying prescription drugs from foreign countries; Decision of Medicare to offer discount drug cards; Price range of drugs in 2004. INSETS: Quick Tips;Price Differences for...

  • Pfizer to explain high cost of prescription drugs. Rosa, Taina // Caribbean Business;9/16/2004, Vol. 32 Issue 39, p18 

    Reports on the seminar aimed at explaining the reason for the high cost of medicine offered by pharmaceutical manufacturer, Pfizer Corp. in Puerto Rico. Outlook of the industry towards the high prices of medicine; Cost associated with developing a single product; Investments involved in research...

  • Industry Forecast Scenario.  // Canada Pharma & Healthcare Report;Q3 2011, Issue 3, p39 

    The article predicts the industrial progress of the Canadian healthcare and pharmaceutical industries. Pharmaceutical spending will be projected to increase to 26.61 billion U.S. dollars by 2015 due to rising need for chronic disease drugs. Healthcare spending will be forecasted to grow by...

  • Your doctor is in. Manson, Joann E. // Glamour;Oct2004, Vol. 102 Issue 10, p114 

    Presents answers to inquiries related to purchase of medications from Canada. Prices of prescription costs; Legal risks associated with the purchase of import pharmaceuticals.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics